Details of the Drug

General Information of Drug (ID: DMH1UV5)

Drug Name
REGN5668
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1/2 [1]
Drug Type
Bispecific antibody
Cross-matching ID
TTD ID
DT1R9E

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ovarian carcinoma antigen CA125 (MUC16) TTC1PS3 MUC16_HUMAN Not Available [1]
T-cell-specific surface glycoprotein CD28 (CD28) TTQ13FT CD28_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Ovarian tissue
The Studied Disease Ovarian cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ovarian carcinoma antigen CA125 (MUC16) DTT MUC16 4.86E-04 5.02 2.6
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.